Skip to main content

Digestive

  • GSK Consumer Healthcare debuts new innovation labs at U.S. headquarters

  • IM HealthScience releases two clinicals supporting efficacy of IBgard and FDgard

    LAS VEGAS – IM HealthScience earlier this week announced results from a pair of clinical trials supporting the use of IBgard and FDgard, respectively.

  • BI launches new combination antacid

    Boehringer Ingelheim is looking to spark some excitement across the antacids aisle with the June launch of its Duo Fusion combination antacid, “from the makers of Zantac,” which couples a fast-acting heartburn remedy with an H2 blocker to provide both immediate and longer-lasting relief from heartburn. “We saw an opportunity to trade up consumers from antacids to an H2 [blocker],” said Marc Rovner, general manager Boehringer Ingelheim Consumer Healthcare, in an interview with Drug Store News.

  • Study: PCP and ER visits for GERD down since OTC PPIs switched

    WASHINGTON - The availability of proton pump inhibitors in the self-care aisles may be responsible for a reduction in doctor visits and trips to the emergency room for gastroesophageal reflux disease (GERD), according to a new study published in the Journal of Clinical Pharmacology published Wednesday.

  • University of Rhode Island pharmacy students take home coveted 'Pepto Bowl'

    KINGSTON, R.I. — The University of Rhode Island College of Pharmacy students Matt Lippertshauser and Ethan Melillo recently took home the "Pepto Bowl"  as part of the annual Student and Pharmacist Self-Care Championship, URI announced Tuesday.

    The pair represented URI in the “Jeopardy!”-style academic competition at the annual New England Pharmacy Convention Sept. 23. Their victory marks the third time in nine years that URI has won the contest, reported College of Pharmacy Clinical Professor Kelly Orr, but it didn't come easy.

  • Study reaffirms safety and tolerability profile of leading IBS medical food

    BOCA RATON, Fla. - IM HealthScience on Monday announced favorable results from its Irritable Bowel Syndrome Safety Update at 6 Months (IBSSU-6), a real-world surveillance study reporting on the safety and tolerability profile of IBgard among an estimated 163,165 patients who used the product.  

  • Hamacher Resource Group certifies 13 merchandisers for Drogueria Betances

    WAUKESHA, Wis. — Hamacher Resource Group has trained and certified 13 merchandisers for Puerto Rican drug wholesaler Drogueria Betances, the company announced Wednesday. The merchandisers completed an extensive, multi-module training program over the course of several months, earning certification from HRG experts. 
     

  • Big OTC brands fuel sales growth

    Sales of OTC medicines continue on a steady pace with dollar volumes up half a billion dollars over the first half of 2016, according to data culled from IRI. Drug Store News earlier this year reported $44 billion in OTC sales for calendar 2015, citing IRI figures.

X
This ad will auto-close in 10 seconds